证券代码：002817 证券简称：黄山胶囊 公告编号：2025-011 安徽黄山胶囊股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1. 本次股东大会不存在出现否决议案的情形。 2. 本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1. 召开时间： （1）现场会议召开时间：2025 年 4 月 25 日（星期五）下午 14:30 （2）网络投票时间：2025 年 4 月 25 日（星期五） 2. 召开地点：安徽省旌德县篁嘉桥经济开发区篁嘉大道 7 号本公司一楼会 议室。 3. 召开方式：本次会议以现场投票与网络投票相结合的方式召开。 4. 召集人：安徽黄山胶囊股份有限公司（以下简称"公司"）第五届董事会。 5. 主持人：董事长李合军先生。 6. 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 （二）会议出席情况 1. 出席会议的总体情况 股东出席的总体情况： 通过现场和网络投票的股东 92 人，代表股份 111,618, ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-013 安徽黄山胶囊股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第十二次会 议（以下简称"本次会议"）通知于 2025 年 4 月 15 日以电话、电子邮件等方式 发出，并于 2025 年 4 月 25 日在公司一楼会议室以现场结合通讯的方式召开。本 次会议由监事会主席张新华先生主持，部分高级管理人员列席了会议，本次会议 应到监事 3 名，实到监事 3 名。本次会议的通知、召集、召开、审议、表决程序 均符合有关法律、行政法规、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 1. 审议通过《公司 2025 年第一季度报告》 经审核，监事会认为董事会编制 2025 年第一季度报告的程序符合法律、行 政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的财务状 况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。 《公司 2025 年第一季度报告 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-012 安徽黄山胶囊股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1. 审议通过《公司 2025 年第一季度报告》 《公司 2025 年第一季度报告》详见公司指定信息披露媒体《证券时报》《上 海证券报》《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）。 表决结果：同意 7 票，反对 0 票，弃权 0 票。本议案提交董事会审议前，已 经董事会审计委员会审议通过。 2. 审议通过《关于公司聘任审计部经理的议案》 具体内容详见公司指定信息披露媒体《证券时报》《上海证券报》《中国证券 报》和巨潮资讯网（http://www.cninfo.com.cn）。 表决结果：同意 7 票，反对 0 票，弃权 0 票。本议案提交董事会审议前，已 经董事会提名委员会和董事会审计委员会审议通过。 3. 审议通过《关于公司聘任副总经理的议案》 具体内容详见公司指定信息披露媒体《证券时报》《上海证券报》《中国证券 报》和 ...

北京市中伦律师事务所 关于安徽黄山胶囊股份有限公司 2024 年度股东大会的 法律意见书 2025 年 4 月 法律意见书 北京市中伦律师事务所 关于安徽黄山胶囊股份有限公司 法律意见书 议审议的议案内容以及这些议案所表述的事实或数据的真实性及准确性发表意 见。 2024 年度股东大会的法律意见书 本所及本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见书所认定的事实真实、 准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或 者重大遗漏，并承担相应法律责任。 致：安徽黄山胶囊股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受安徽黄山胶囊股份有限公 司（以下简称"公司"）委托，指派本所律师对公司 2024 年度股东大会（以下 简称"本次股东大会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 中国证券监督管理委员会（以下简称 ...

Financial Performance - The company's revenue for Q1 2025 was ¥119,039,034.77, representing a slight increase of 0.53% compared to ¥118,410,927.98 in the same period last year[5] - Net profit attributable to shareholders increased by 22.90% to ¥18,837,042.65 from ¥15,327,124.06 year-on-year[5] - Basic and diluted earnings per share rose by 20.00% to ¥0.06, up from ¥0.05 in the same period last year[5] - Total operating revenue for the current period reached ¥119,039,034.77, a slight increase of 0.53% compared to ¥118,410,927.98 in the previous period[23] - Net profit for the current period was ¥18,973,875.62, representing a 22.93% increase from ¥15,501,012.90 in the previous period[24] - Operating profit rose to ¥21,911,258.36, an increase of 24.00% compared to ¥17,534,852.53 in the previous period[24] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching ¥7,500,281.96, a 140.57% increase from a negative cash flow of ¥18,488,513.56 in the previous year[5] - Cash flow from operating activities generated a net amount of ¥7,500,281.96, a significant recovery from a negative cash flow of ¥18,488,513.56 in the previous period[25] - The company's cash and cash equivalents at the end of the reporting period amount to ¥318,248,590.34, down from ¥341,642,031.24 at the beginning of the period[20] - Cash and cash equivalents at the end of the period totaled ¥58,280,918.52, down from ¥187,885,133.95 at the end of the previous period[26] - The company reported a significant decrease in investment activities cash flow, down by 1116.22% to a negative ¥38,850,400 due to large certificate purchases[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,103,184,328.00, reflecting a 1.53% increase from ¥1,086,534,605.98 at the end of the previous year[5] - Total assets amount to ¥1,103,184,328.00, compared to ¥1,086,534,605.98 at the beginning of the period, indicating an increase of about 1.5%[21] - Total liabilities decreased to ¥166,458,068.60 from ¥168,773,049.88, a reduction of approximately 1.4%[21] - Non-current assets total ¥512,132,076.06, up from ¥496,521,973.13, representing an increase of approximately 3.2%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,378[19] - The largest shareholder, Shandong Lutai Holding Group Co., Ltd., holds 29.99% of shares, totaling 89,699,541 shares[19] - The number of shares held by the top ten unrestricted shareholders includes significant holdings by Shandong Lutai Holding Group and Yu Chunming, indicating concentrated ownership[19] Cost Management and Efficiency - The company plans to continue focusing on cost reduction and efficiency improvements to enhance profitability in the upcoming quarters[27] - Total operating costs decreased to ¥98,353,399.04, down 3.66% from ¥102,310,914.53 in the previous period[23] - The company experienced a 44.89% increase in income tax expenses, amounting to an increase of ¥914,800 due to higher profits[17] Other Financial Metrics - The company's weighted average return on equity improved to 2.05%, up from 1.69% in the previous year[5] - The company's retained earnings increased to ¥481,530,246.47 from ¥462,693,203.82, showing a growth of about 4.0%[22] - Accounts receivable increased to ¥124,284,985.41 from ¥110,369,995.29, reflecting a growth of approximately 12.9%[20] - The company incurred a credit impairment loss of ¥802,849.42, an improvement from a loss of ¥914,664.88 in the previous period[24] - The increase in receivables financing at the end of the period was ¥13,670,400, representing a growth of 48.72%[7] - The company reported a decrease in short-term borrowings, reflecting improved liquidity management[21]

证券之星消息，2025年4月16日黄山胶囊（002817）发布公告称公司于2025年4月16日召开业绩说明会。 具体内容如下： 问：公司的明胶空心胶囊DMF备案号已在FDA与制剂关联。请这是否意味着公司有机会拓展国际市 场？目前在国际市场上的布局和进展如何？ 答：尊敬的投资者您好，我司明胶空心胶囊DMF备案号在FD与制剂关联后，公司明胶空心胶囊已供给 多家国内制药企业用于出口美国市场的药品。公司积极开拓国际市场，2024年度先后参加了泰国亚洲保 健品、欧洲米兰CPHI等海外知名展会，获得了海外客户的认可，并与某东南亚客户签订5年战略合作协 议。感谢您的关注！ 问：你好，请在行业竞争加剧的情况下，公司如何保持和升自身的管理效率和运营成本控制能力？ 答：尊敬的投资者您好,在行业竞争加剧的情况下，公司采取了以下措施提升管理效率与运营成本控制 能力 在管理效率方面，持续推进制度改革赋能，优化决策流程；完善采购、生产、销售、财务等管理制度和 审批控制流程，通过信息化系统进行控制监督；强化风险管理和内部控制体系建设，搭建内部审计监督 体系，防范经营风险。 在运营成本控制方面，牢固树立"过紧日子、苦日子"思想，加强对供应商 ...

Group 1: Market Expansion and International Presence - The company has obtained DMF registration for its gelatin capsules with the FDA, enabling it to supply domestic pharmaceutical companies for export to the U.S. market [2] - In 2024, the company participated in major international exhibitions, such as the Asia Health Products in Thailand and CPHI in Milan, securing recognition from overseas clients and signing a 5-year strategic cooperation agreement with a Southeast Asian client [3] Group 2: Management Efficiency and Cost Control - To enhance management efficiency, the company is implementing institutional reforms, optimizing decision-making processes, and strengthening risk management and internal control systems [3] - The company emphasizes a "tight budget" approach, conducting supplier comparisons and utilizing diversified procurement methods to reduce costs [3] Group 3: Product Structure and Market Demand - The demand for hollow capsules is expected to grow due to aging populations and increased health awareness, with the company producing over 40 billion capsules annually across various types [4] - The company has established long-term partnerships with pharmaceutical and health product companies to quickly secure orders during market surges [4] Group 4: Future Development Strategy - The company focuses on becoming a customized service expert in capsule production, enhancing production efficiency and product quality through innovation and smart manufacturing [4] - Plans for mergers and acquisitions will be disclosed in accordance with relevant regulations if they arise [4] Group 5: Financial Performance - In 2024, the company achieved a revenue of 473.48 million yuan and a net profit of 49.25 million yuan, distributing cash dividends of 19.44 million yuan to investors [5] - The company has maintained a stable governance structure and has not experienced annual losses since its listing, with no current risk of ST or mandatory delisting [6] Group 6: Industry Outlook - The hollow capsule market is projected to grow due to favorable national policies and increasing health consciousness, although challenges such as industry competition and trade protectionism may introduce uncertainties [6]

Core Viewpoint - Huangshan Capsule (002817.SZ) reported a revenue of 473 million yuan for 2024, a year-on-year increase of 2.31%, but with a decline in net profit. The company has shown significant growth in its two high-end products, indicating a successful optimization of its product structure despite industry challenges [1][2]. Group 1: Financial Performance - The company achieved a net profit of 49.25 million yuan and a non-recurring net profit of 47.16 million yuan, reflecting a decline compared to the previous year [1]. - Revenue from enteric-coated capsules reached 73.74 million yuan, growing by 25.23%, while plant-based capsules generated 53.69 million yuan, with a growth of 64.37% [1][3]. - The revenue distribution among the three main product categories is as follows: gelatin capsules (73.15%), enteric-coated capsules (15.52%), and plant-based capsules (11.33%) [3]. Group 2: Product Development and Innovation - Huangshan Capsule has established a comprehensive product matrix, including gelatin, enteric-coated, and HPMC (plant-based) capsules, with a production capacity exceeding 40 billion capsules annually [2][3]. - The company invested 14.01 million yuan in R&D for 2024, applying for five new patents and receiving four, enhancing its technological innovation capabilities [3]. - The rapid growth of high-end products is attributed to the company's focus on technological innovation and continuous investment [3]. Group 3: Market Position and Strategy - The company is one of the largest manufacturers of pharmaceutical capsules in China, benefiting from its compliance and technological advantages amid industry consolidation [4]. - Huangshan Capsule is advancing its digital transformation, with over 20 technical upgrades in its workshops planned for 2024 [4][5]. - The company has established a robust marketing network and partnerships with major pharmaceutical companies, enhancing customer loyalty and market presence [5]. Group 4: Global Expansion - Huangshan Capsule is actively expanding into international markets, having achieved FDA DMF registration, which allows for the export of high-end products to Europe and the U.S. [6][7]. - In 2024, overseas sales reached 79.66 million yuan, a growth of 80.85% compared to 2023, accounting for 16.82% of total revenue [7]. - The global hollow capsule market is projected to grow from 6.219 billion yuan in 2023 to 9.405 billion yuan by 2029, with a compound annual growth rate of 5.60% [8]. Group 5: Profit Distribution - The company announced a profit distribution plan for 2024, proposing a cash dividend of 0.38 yuan per 10 shares, totaling 11.37 million yuan, marking the highest cumulative dividend of 19.44 million yuan in its history [8].

证券代码：002817 证券简称：黄山胶囊 公告编号：2025-008 安徽黄山胶囊股份有限公司 关于召开 2024 年度股东大会通知的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、召开会议的基本情况 第五届董事会第十一次会议决议提请召开股东大会。 法规、部门规章、规范性文件和《公司章程》的规定。 现场会议时间：2025 年 4 月 25 日（星期五）下午 14:30 网络投票时间：2025 年 4 月 25 日 其中，通过深圳证券交易所交易投票系统进行网络投票的具体时间为：2025 年 4 月 25 日 9:15—9:25，9:30—11:30 和 13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 4 月 25 日 （1）现场投票：股东本人出席现场会议或者通过授权委托书（见附件二） 委托他人出席现场会议。 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向公司股东提供网络形式的投票平台，股东可 以在网络投票时间内通过上述系统行使表决权 ...

第一章 总则 第一条 为进一步规范安徽黄山胶囊股份有限公司（以 下简称"黄山胶囊"或"公司"）对外捐赠行为，加强对外 捐赠事项的管理，更好地履行社会责任，提升公司形象，同 时确保公司资产的合理使用和股东权益的有效维护，根据 《中华人民共和国公益事业捐赠法》《中华人民共和国公司 法》等国家有关法律法规以及《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》 《公司章程》 等有关规定，结合公司实际情况，制定本办法。 第二条 本制度适用于黄山胶囊及其全资、控股子公司。 未经授权，下属子公司不得开展对外捐赠事项。 第三条 本制度所称"对外捐赠"，是指公司自愿无偿 将其有权处分的合法财产赠与合法的受赠人，用于与生产经 营活动没有直接关系的公益事业的行为。 第四条 公司开展对外捐赠活动应当遵循以下原则： （一）一致性原则。公司开展对外捐赠是企业履行社会 责任的重要组成部分，是对企业品牌建设、无形资产培育的 长期投资，要结合公司发展战略，紧密围绕企业文化，确保 与企业的战略目标相一致。 （五）诚实守信原则。经审批已经向社会公众或者受赠 对象承诺捐赠的，必须诚实履行，未经审批不能随意改变捐 赠承诺。 第 ...